Arcutis Biotherapeutics Stock Filter Stocks by Fundamentals
| ARQT Stock | USD 13.24 0.43 3.15% |
Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.
Arcutis | Shares Owned by Institutions |
Arcutis Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 830.3M | 1.0B | 1.0B | 223.9M | 257.4M | 244.6M | |
| Enterprise Value | 767.3M | 943.2M | 1.0B | 341.4M | 392.6M | 373.0M |
Arcutis Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcutis Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Arcutis Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcutis Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcutis Biotherapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.5 M | Ensign Peak Advisors Inc | 2024-09-30 | 2.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 2.3 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-09-30 | 2.1 M | Stempoint Capital Lp | 2024-09-30 | 1.8 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.7 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.6 M | Goldman Sachs Group Inc | 2024-09-30 | 1.6 M | J. Goldman & Co Lp | 2024-09-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 11.7 M | Rubric Capital Management Lp | 2024-09-30 | 11 M |
Arcutis Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.48 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 1.93 % | ||||
| Shares Owned By Institutions | 98.07 % | ||||
| Number Of Shares Shorted | 20.22 M | ||||
| Price To Book | 10.21 X | ||||
| Price To Sales | 11.54 X | ||||
| Revenue | 59.61 M | ||||
| Gross Profit | 124.24 M | ||||
| EBITDA | (227.43 M) | ||||
| Net Income | (262.14 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 205.92 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (247.06 M) | ||||
| Short Ratio | 9.21 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 19.5 | ||||
| Number Of Employees | 296 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.6 B | ||||
| Total Asset | 341.37 M | ||||
| Retained Earnings | (981.9 M) | ||||
| Working Capital | 283.76 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
| Net Asset | 341.37 M |
About Arcutis Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.